AR Signaling and Cell Cycle Regulation in Prostate Cancer
Co-targeting AR and the Cell Cycle
Biological parallels between PCa and HR+ BCa:
Continued ER and AR signaling drive uncontrolled cellular proliferation by activating CDK4/61,2
AR=androgen receptor; ARi=androgen receptor inhibitor; BCa=breast cancer; CDK4/6=cyclin dependent kinase 4 & 6; CDK4/6i=cyclin dependent kinase 4 & 6 inhibitor; ER=estrogen receptor; ERi=estrogen receptor inhibitor; HR+=hormone receptor positive; PCa=prostate cancer.
Enhancing AR-Targeted Approaches
This animation provides an overview of the androgen receptor (AR) signaling pathway and its interaction with cell cycle regulation.
This slide deck examines the unmet need in advanced prostate cancer, the AR pathway, its interaction with cell cycle regulation, and novel approaches to enhance AR-targeting.
This infographic provides an overview of the androgen receptor (AR) signaling pathway and the rationale to target the cell cycle in advanced prostate cancer.
- Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 2008;6:e001.
- Wander SA, O’Brien N, Litchfield L, et al. Targeting CDK4 and 6 in cancer therapy: Emerging preclinical insights related to abemaciclib. Oncologist. 2022;27:811-821.
- Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog. 2011;10:20.
- Brighi N, Conteduca V, Lolly C, et al. The cyclin-dependent kinases pathway as a target for prostate cancer treatment: Rationale and future perspectives. Crit Rev Onc/Hem. 2021;157
- Nabieva N, Fasching PA. CDK4/6 Inhibitors-Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer. Cancers (Basel). 2023;15(6):1763.